Hideyuki Kano

Hideyuki Kano

Auto-generated profile, based on publicly available information

Hideyuki Kano

Departments of Neurological Surgery and

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
DKDouglas Msc Kondziolka
Douglas Msc Kondziolka
APAgam D. Ba Patel
Agam D. Ba Patel
HKHideyuki Kano
Hideyuki Kano
JFJohn C. Flickinger
John C. Flickinger
LLL. Dade Lunsford
L. Dade Lunsford
Background: Gamma knife stereotactic radiosurgery (SRS) has become an important management strategy for patients with meningiomas. Although prior reports have studied early tumor control, neurological response, and associated morbidity, our purpose was to use clinical and imaging studies to determine whether long-term outcomes remain stable over time. Materials and Methods: We studied 290 consecutive patients (92 men and 198 women) who underwent gamma knife SRS for a meningioma between 1987 and 1997. The median tumor margin dose was 15 Gy and the median tumor volume was 5.5 mL. Target definition was performed using contrast enhanced computed tomography in 72 patients and magnetic resonance imaging in 218 patients. The median patient age at radiosurgery was 61 years. Twenty patients had a history of fractionated radiation therapy, 136 patients had undergone a subtotal resection, and 22 patients had recurrences after initial gross total resection. Results: The overall tumor control rate was 91%. Twenty-six patients (9%) had evidence of delayed local tumor growth and 44 (15%) had regional tumor progression, which occurred at a median of 38 months. The 10- and 20-year actuarial rates of freedom from tumor progression of the targeted tumor were 87.7%±2.5% and 87.2%±4.2%. Of 234 patients who had symptoms before SRS (n=62, 26%) improved, 126 (54%) had no change in symptoms and 46 (20%) gradually worsened. Thirty-two of 34 (94%) asymptomatic patients remained asymptomatic. We found no difference in long-term tumor control rates between patients who had undergone craniotomy before radiosurgery (89%) and patients who underwent primary radiosurgery (93.1%). Adverse radiation effects were detected in 3.1% of patients. Factors associated with worse progression-free survival included prior radiation therapy (P<0.0001) and higher grade meningioma (P<0.0001). At a median of 8.7 years after SRS, 137 patients were dead at a median age of 77 years. Conclusions: We found that gamma knife SRS provided durable tumor control with low morbidity in meningioma patients.

18 September 2019 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SJStephen Johnson
Stephen Johnson
HKHideyuki Kano
Hideyuki Kano
AFAndrew Faramand
Andrew Faramand
MPMatthew Pease
Matthew Pease
ANAya Nakamura
Aya Nakamura
LLL. Dade Lunsford
L. Dade Lunsford

1 January 2017 in Stroke
Verified
Journal Article
Closed access
PDF file
HKHideyuki Kano
Hideyuki Kano
JFJohn C. Flickinger
John C. Flickinger
DTDaniel Tonetti
Daniel Tonetti
AHAlan Hsu
Alan Hsu
HYHuai-Che Yang
Huai-Che Yang
LLL. Dade Lunsford
L. Dade Lunsford
Background and Purpose—: We evaluated risk factors associated with the development of adverse radiation effects (ARE) after stereotactic radiosurgery (SRS) for cerebral arteriovenous malformations (AVMs). Methods—: We evaluated 755 patients with AVM who underwent a single Gamma Knife SRS procedure with at least a 2-year minimum follow-up. Eighty-seven patients (12%) underwent previous resection and 128 (17%) had previous embolization. The median target volume was 3.6 mL (range, 0.1–26.3 mL). The median margin dose was 20 Gy (range, 13–27 Gy). Results—: Fifty-five patients (7%) developed symptomatic ARE at a median follow-up of 75 months. The cumulative rates of symptomatic ARE were 3.2%, 5.8%, 6.7%, and 7.5% at 1, 2, 3, and 5 years, respectively. Factors associated with a higher rate of developing symptomatic ARE included larger AVM volume, higher margin dose, larger 12-Gy volume, higher Spetzler–Martin grade, and higher radiosurgery-based score. The rates of developing symptomatic ARE were higher in the brain stem (22%) or thalamus (16%), compared with AVMs located in other brain locations (4%–8%). Nineteen patients (3%) sustained irreversible new neurological deficits related to ARE, and 1 patient died. The rates of irreversible symptomatic ARE were 0.8%, 1.9%, 2.1%, and 2.8% at 1, 2, 3, and 5 years, respectively. The 5-year cumulative rates of irreversible symptomatic ARE were 9.1% in thalamus, 12.1% in brain stem, and 1.4% in other locations. Conclusions—: The knowledge of ARE risk rates after AVM radiosurgery can assist informed consent for patients with AVM, their families, and healthcare providers.

3 September 2013 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
NLNeal Luther
Neal Luther
DKDouglas Kondziolka
Douglas Kondziolka
HKHideyuki Kano
Hideyuki Kano
SMSeyed H. Mousavi
Seyed H. Mousavi
JEJohnathan A. Engh
Johnathan A. Engh
LLL. Dade Lunsford
L. Dade Lunsford
BACKGROUND: Stereotactic radiosurgery (SRS) to the resection bed of a brain metastasis is an important treatment option. OBJECTIVE: To identify factors associated with tumor progression after SRS of the resection bed of a brain metastasis and to evaluate patterns of failure for patients who eventually had tumor progression. METHODS: We performed a retrospective analysis of 120 patients who underwent tumor bed radiosurgery after an initial gross total resection. The mean imaging follow-up time was 55 weeks. The median margin dose was 16 Gy. Forty-seven patients (39.2%) underwent whole-brain radiation therapy before or shortly after SRS. RESULTS: Local tumor control was achieved in 103 patients (85.8%). Progression-free survival was 96% at 6 months, 87% at 12 months, and 74% at 24 months. Recurrence most commonly occurred deep in the cavity (65%) outside the planned treatment volume (PTV) margin (53%). PTV, cavity diameter, and a margin dose < 16 Gy significantly correlated with local failure. For patients with PTVs ≥ 8.0 cm3, local progression-free survival declined to 93% at 6 months, 83% at 12 months, and 65% at 24 months. Development or progression of distant metastases occurred in 40% of patients. Whole-brain radiation therapy was not associated with improved local control. CONCLUSION: Resection bed SRS for brain metastases provided excellent local control. The cavity PTV is predictive of tumor control. Because failure usually occurs outside the PTV, inclusion of a judicious 2- to 3-mm margin beyond the area of postoperative enhancement may be prudent.

1 September 2013 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
HKHideyuki Kano
Hideyuki Kano
KPKyun-Jae Park
Kyun-Jae Park
DKDouglas Kondziolka
Douglas Kondziolka
AIAditya Iyer
Aditya Iyer
XLXiaomin Liu
Xiaomin Liu
LLL. Dade Lunsford
L. Dade Lunsford
BACKGROUND:. Stereotactic radiosurgery (SRS) is an important option for patients with cavernous sinus meningiomas.OBJECTIVE:. To evaluate cranial nerve

1 July 2018 in Journal of Neurosurgery
Verified
Journal Article
Closed access
KPKyung-Jae Park
Kyung-Jae Park
HKHideyuki Kano
Hideyuki Kano
AIAditya Iyer
Aditya Iyer
XLXiaomin Liu
Xiaomin Liu
DTDaniel A. Tonetti
Daniel A. Tonetti
LLL. Dade Lunsford
L. Dade Lunsford
OBJECTIVE: The authors of this study evaluate the long-term outcomes of stereotactic radiosurgery (SRS) for cavernous sinus meningioma (CSM). METHODS: The authors retrospectively assessed treatment outcomes 5–18 years after SRS in 200 patients with CSM. The median patient age was 57 years (range 22–83 years). In total, 120 (60%) patients underwent Gamma Knife SRS as primary management, 46 (23%) for residual tumors, and 34 (17%) for recurrent tumors after one or more surgical procedures. The median tumor target volume was 7.5 cm 3 (range 0.1–37.3 cm 3 ), and the median margin dose was 13.0 Gy (range 10–20 Gy). RESULTS: Tumor volume regressed in 121 (61%) patients, was unchanged in 49 (25%), and increased over time in 30 (15%) during a median imaging follow-up of 101 months. Actuarial tumor control rates at the 5-, 10-, and 15-year follow-ups were 92%, 84%, and 75%, respectively. Of the 120 patients who had undergone SRS as a primary treatment (primary SRS), tumor progression was observed in 14 (11.7%) patients at a median of 48.9 months (range 4.8–120.0 months) after SRS, and actuarial tumor control rates were 98%, 93%, 85%, and 85% at the 1-, 5-, 10-, and 15-year follow-ups post-SRS. A history of tumor progression after microsurgery was an independent predictor of an unfavorable response to radiosurgery (p = 0.009, HR = 4.161, 95% CI 1.438–12.045). Forty-four (26%) of 170 patients who had presented with at least one cranial nerve (CN) deficit improved after SRS. Development of new CN deficits after initial microsurgical resection was an unfavorable factor for improvement after SRS (p = 0.014, HR = 0.169, 95% CI 0.041–0.702). Fifteen (7.5%) patients experienced permanent CN deficits without evidence of tumor progression at a median onset of 9 months (range 2.3–85 months) after SRS. Patients with larger tumor volumes (≥ 10 cm 3 ) were more likely to develop permanent CN complications (p = 0.046, HR = 3.629, 95% CI 1.026–12.838). Three patients (1.5%) developed delayed pituitary dysfunction after SRS. CONCLUSIONS: This long-term study showed that Gamma Knife radiosurgery provided long-term tumor control for most patients with CSM. Patients who underwent SRS for progressive tumors after prior microsurgery had a greater chance of tumor growth than the patients without prior surgery or those with residual tumor treated after microsurgery.